Approval for a new device design and new manufacturing location.  The device, as modified and with revised labeling, will be marketed under the trade name dilapan-s and is indicated for dilatation of the cervix uteri prior to termination of pregnancy up to 16 weeks gestation.  A single dilapan-s is inserted into the endocervical canal and may remain in situ for up to four hours.  The device will be manufactured at a new facility located at gelmed international, in the czech republic and sterilized at a contract sterilization facility located at bioster a. s., in the czech republic.